Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 14/20 | 0.53 |
| ▸ | BCR | P11274 | 12/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | GOT1 | P17174 | 1/20 | 0.42 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.41 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 2/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2695612 | 0.90 | CSF1R (0.44) | ABL1BCRMAPTGOT1TTBK1 | |
| SCHEMBL2695026 | 0.88 | ABL1 (0.39) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL2695525 | 0.88 | CSF1R (0.41) | ABL1BCRTTBK1TTBK2SYK | |
| SCHEMBL2696012 | 0.85 | CSF1R (0.42) | SYK | |
| SCHEMBL2695887 | 0.84 | CSF1R (0.39) | SYK | |
| SCHEMBL2696726 | 0.84 | SYK (0.44) | ABL1BCRSYK | |
| SCHEMBL2693114 | 0.83 | CSF1R (0.42) | SYK | |
| SCHEMBL2692967 | 0.83 | SYK (0.42) | SYK | |
| SCHEMBL2693420 | 0.81 | CSF1R (0.45) | SYK | |
| SCHEMBL2693148 | 0.81 | SYK (0.45) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150353495-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | ALEXION PHARMACEUTICALS, INC. | 2015-12-10 | — | — | US | claimed |
| EP-2635557-A2 | NICOTINAMIDES AS JAK KINASE MODULATORS | Portola Pharmaceuticals, Inc. (US) | 2013-09-11 | — | — | EP | claimed |
| WO-2012061428-A2 | NICOTINAMIDES AS JAK KINASE MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | WO | claimed |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | claimed |
| EP-2975027-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | Portola Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150353495-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | ALEXION PHARMACEUTICALS, INC. | 2015-12-10 | — | — | US | disclosed |
| US-9102625-B2 | Nicotinamides as JAK kinase modulators | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| EP-2635557-A2 | NICOTINAMIDES AS JAK KINASE MODULATORS | Portola Pharmaceuticals, Inc. (US) | 2013-09-11 | — | — | EP | disclosed |
| WO-2012061428-A2 | NICOTINAMIDES AS JAK KINASE MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353495-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | ABL1 64/4885BCR 999/4885KDM4E 1791/4885 |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | ABL1 64/4885BCR 999/4885KDM4E 1791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.